Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moosa, M.-Y. S.
Right arrow Articles by Chandrasekar, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moosa, M.-Y. S.
Right arrow Articles by Chandrasekar, P. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 209-213
© 2002 The British Society for Antimicrobial Chemotherapy

Brief report

Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis

Mahomed-Yunus S. Moosa, George J. Alangaden, Elias Manavathu and Pranatharthi H. Chandrasekar,*

Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA

Emergence of resistance to antifungal drugs during therapy for invasive aspergillosis has received scant attention. We recovered Aspergillus isolates from six patients with invasive aspergillosis, who were receiving amphotericin B before fungal isolation. Although isolates were susceptible to amphotericin B in vitro, none of the patients survived. The MIC of amphotericin B for isolates was similar to that for isolates from 35 patients with no prior exposure to amphotericin B. Laboratory attempts to produce amphotericin B resistance in Aspergillus were unsuccessful. These data indicate that emergence of resistance to amphotericin B is uncommon during therapy for invasive aspergillosis.

* Correspondence address. Division of Infectious Diseases, 4 Yellow Center, Room 415, Harper Hospital, 3990 John R, Detroit, MI 48201, USA. Tel: +1-313-745-9649; Fax: +1-313-993-0302; E-mail: pchandrasekar{at}intmed.wayne.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eukaryot CellHome page
L. E. Cowen and W. J. Steinbach
Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance
Eukaryot. Cell, May 1, 2008; 7(5): 747 - 764.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
N. Singh and D. L. Paterson
Aspergillus Infections in Transplant Recipients
Clin. Microbiol. Rev., January 1, 2005; 18(1): 44 - 69.
[Abstract] [Full Text] [PDF]

Home page
 J Med MicrobiolHome page
E. Dannaoui, J. Meletiadis, A.-M. Tortorano, F. Symoens, N. Nolard, M.-A. Viviani, M.-A. Piens, B. Lebeau, P. E. Verweij, and R. Grillot
Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients
J. Med. Microbiol., February 1, 2004; 53(2): 129 - 134.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.